18F-mFBG Imaging for Neural Crest Tumors
Trial Summary
What is the purpose of this trial?
This is a prospective Phase 2 study being performed to document the relationship between 18F-mIBG positron emission tomography (PET) findings in subjects, and expression of the norepinephrine transporter. In addition to collecting safety data for the imaging agent, the study aims to:* compare the findings against other catacholamine transporters* evaluate the imaging results at different time points and in different organs* assess the quality of images with lower doses* compare the ability to detect neuroblastoma lesions against other imaging agents, and in other tumors
Research Team
Alice Lee, MD
Principal Investigator
Montefiore Medical Center/Albert Einstein College of Medicine
Eligibility Criteria
This trial is for individuals with neuroblastoma, paraganglioma, or pheochromocytoma. It's designed to see how well a new imaging agent called 18F-mFBG shows these tumors and organs affected by the sympathetic nervous system on PET scans.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Imaging and Tissue Sampling
Participants undergo 18F-mFBG PET imaging and tissue sampling for NET expression analysis
Follow-up
Participants are monitored for safety and effectiveness after imaging and tissue sampling
Treatment Details
Interventions
- 18F-mFBG
Find a Clinic Near You
Who Is Running the Clinical Trial?
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Lead Sponsor
Albert Einstein College of Medicine
Collaborator